Tredegar SEC Filings

The Form 4 filed on 07/03/2025 reports routine equity-compensation activity by Forte Biosciences (FBRX) CEO, Chair and Director Paul A. Wagner. On 07/01/2025 he converted 1,250 restricted stock units into an equal number of common shares (code M) at a $0 exercise price. To cover statutory taxes, 98 shares were automatically surrendered (code F) at $12.44 each. Following the transactions, Wagner now owns 80,940 FBRX shares directly and retains 7,500 unvested RSUs.

No open-market buying or selling occurred, no cash changed hands, and the share count involved is immaterial relative to Forte’s public float, so market impact should be limited. Nevertheless, the filing incrementally increases insider ownership and signals that vesting under the 2021 Equity Incentive Plan continues as scheduled.

Form 4 highlights for ZimVie Inc. (ZIMV): Senior Vice President and Chief Commercial Officer Indraneel Kanaglekar reported an automatic share disposition on 07/01/2025 related to RSU tax withholding (transaction code F). Exactly 145 common shares were withheld at $9.61 per share to cover taxes upon vesting. Following the transaction, the insider still beneficially owns 62,851 shares, which now include 837 shares purchased through the company’s ESPP on 05/30/2025. No derivative securities were involved, and there was no open-market sale; the movement is strictly administrative. The filing indicates continued sizeable ownership by the executive, suggesting alignment with shareholders, while the 145-share reduction represents less than 0.25% of the reported holdings and is unlikely to exert market impact.

Equity Residential (EQR) – Form 4 insider filing

Director Tahsinul Zia Huque received 3,393 Series 2025D restricted units (RUs) of ERP Operating Limited Partnership on 1 July 2025 as part of the REIT’s annual long-term compensation program. Each RU automatically converts, subject to tax-capital targets, into one OP Unit that is exchangeable for one Equity Residential common share (or cash) at the company’s option.

• Vesting: 1 July 2026
• Post-vesting holding restriction: until 1 July 2027
• Expiration: 1 July 2035 (if conversion target not met)
• Ownership form: Direct

No shares were sold; the grant was recorded at $0 cost, indicating a routine equity-based award rather than an open-market purchase. The transaction modestly increases insider equity alignment but is immaterial to EQR’s capital structure.

JPMorgan Chase Financial Company LLC is offering Structured Investments Review Notes linked to the MerQube US Tech+ Vol Advantage Index (MQUSTVA), fully and unconditionally guaranteed by JPMorgan Chase & Co. The preliminary terms reveal a five-year note (pricing expected 8 Jul 2025; maturity 11 Jul 2030) that can be automatically called on 48 monthly review dates starting 8 Jul 2026 if the Index closes at or above its initial level (the “Call Value”). When called, investors receive their $1,000 principal plus a Call Premium Amount that starts at ≥17.0% ($170) and escalates to ≥85.0% ($850) by the final review date.

If the notes are not called, principal is protected only within a 15% buffer. At maturity, holders incur 1-for-1 downside exposure beyond that threshold, risking up to 85% capital loss. The structure pays no periodic coupons or dividends and offers no upside beyond the fixed Call Premium schedule.

Key structural features

• Underlying index drag: the Index deducts 6.0% p.a. daily and applies a notional SOFR+0.50% financing cost to its exposure to the Invesco QQQ Trust (QQQ). These deductions will cause the Index to significantly trail an unadjusted Nasdaq-100 exposure, increasing the chance that the notes finish below the buffer.
• Leverage & volatility targeting: weekly rebalancing sets QQQ exposure at 35%/implied vol., capped at 500%, meaning the Index is often leveraged in calm markets and can be under-invested when volatility spikes.
• Credit risk: payments depend on JPMorgan Financial (issuer) and JPMorgan Chase & Co. (guarantor). Estimated value if priced today is $907.20 per $1,000, at least $900 at pricing, indicating 9–10% issuance costs.
• Liquidity: the notes will not be exchange-listed; secondary market is limited to JPMS bid, likely at a discount.
• Denominations: $1,000 minimum; CUSIP 48136FKB7.

Risk highlights disclosed

• Potential for 85% principal loss.
• Index performance drag from 6.0% deduction and financing cost.
• No interest or dividend payments; limited upside to scheduled premiums.
• Automatic call may force reinvestment risk after as little as one year.
• Conflicts of interest: JPM affiliates co-developed the Index and hold a 10% stake in MerQube.

The product targets investors willing to exchange significant downside risk and complexity for the possibility of double-digit call premiums, contingent on the leveraged, fee-laden Index outperforming its initial level on monthly observation dates.

Tredegar Corporation (TG) – Form 4 insider transaction

Director Carl E. Tack III reported an open-market purchase of Tredegar common shares on 01 July 2025. The filing shows an acquisition (Transaction Code A) of 2,513 shares at an average price of $8.95 per share, for an estimated outlay of roughly $22.5 thousand. Following the purchase, Tack’s direct ownership stands at 70,215 shares. No derivative securities were involved, and this is a single-person filing.

The transaction modestly increases insider ownership and may signal incremental confidence by the board member, although the dollar value is relatively small compared with Tredegar’s market capitalization.